calcitonin(redirected from Miacalcic)
Also found in: Dictionary, Thesaurus, Encyclopedia.
Related to Miacalcic: Miacalcin Nasal Spray
APO-Calcitonin, Calcimar, Caltine, Fortical, Miacalcic (UK), Miacalcin, Miacalcin Nasal Spray, Sandoz Calcitonin
Pharmacologic class: Hormone (calcium-lowering)
Therapeutic class: Hypocalcemic
Pregnancy risk category C
Directly affects bone, kidney, and GI tract. Decreases osteoclastic osteolysis in bone; also reduces mineral release and collagen breakdown in bone and promotes renal excretion of calcium. In pain relief, acts through prostaglandin inhibition, pain threshold modification, or beta-endorphin stimulation.
Injection: 0.5 mg/ml (human), 1 mg/ml (human), 200 international units/ml in 2-ml vials (salmon)
Nasal spray (salmon): 200 international units/actuation, metered nasal spray in 3.7 ml-bottle
⊘Indications and dosages
➣ Postmenopausal osteoporosis
Adults:Calcitonin (salmon)-100 international units/day I.M. or subcutaneously, or 200 international units/day intranasally with concurrent supplemental calcium and vitamin D
➣ Paget's disease of bone (osteitis deformans)
Adults:Calcitonin (salmon)-Initially, 100 international units/day I.M. or subcutaneously; after titration, maintenance dosage is 50 to 100 international units daily or every other day (three times weekly). Calcitonin (human)-0.5 mg I.M. or subcutaneously daily, reduced to 0.25 mg daily.
Adults:Calcitonin (salmon)-4 international units/kg I.M. or subcutaneously q 12 hours; after 1 or 2 days, may increase to 8 international units/kg q 12 hours; after 2 more days, may increase further, if needed, to 8 international units q 6 hours.
• Hypersensitivity to drug or salmon
• Pregnancy or breastfeeding
Use cautiously in:
• renal insufficiency, pernicious anemia
☞ Before salmon calcitonin therapy begins, perform skin test, if prescribed. Don't give drug if patient has positive reaction. Have epinephrine available.
• Bring nasal spray to room temperature before using.
• Give intranasal dose as one spray in one nostril daily; alternate nostrils every day.
• To minimize adverse effects, give at bedtime.
• Rotate injection sites to decrease inflammatory reactions.
CNS: headache, weakness, dizziness, paresthesia
CV: chest pain
EENT: epistaxis, nasal irritation, rhinitis
GI: nausea, vomiting, diarrhea, epigastric pain or discomfort
GU: urinary frequency
Musculoskeletal: arthralgia, back pain
Other: altered taste, allergic reactions including facial flushing, swelling, and anaphylaxis
Drug-drug.Previous use of bisphosphonates (alendronate, etidronate, pamidronate, risedronate): decreased response to calcitonin
• Monitor for adverse reactions during first few days of therapy.
• Assess alkaline phosphatase level and 24-hour urinary excretion of hydroxyproline.
• Check urine for casts.
• Monitor serum electrolyte and calcium levels.
• Instruct patient to take drug before bedtime to lessen GI upset. Tell him to call prescriber if he can't maintain his usual diet because of GI upset.
• Inform patient using nasal spray that runny nose, sneezing, and nasal irritation may occur during first several days as he adjusts to spray.
• Instruct patient to bring nasal spray to room temperature before using.
• Advise patient to blow nose before using spray, to take intranasal dose as one spray in one nostril daily, and to alternate nostrils with each dose.
• Tell patient to discard unrefrigerated bottles of calcitonin (salmon) nasal spray after 30 days.
• Encourage patient to consume a diet rich in calcium and vitamin D.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs mentioned above.
calcitonin/cal·ci·to·nin/ (-to´nin) a polypeptide hormone secreted by C cells of the thyroid gland, and sometimes of the thymus and parathyroids, which lowers calcium and phosphate concentration in plasma and inhibits bone resorption. Preparations (c.-human, c.-salmon) are used in the treatment of osteitis deformans, postmenopausal osteoporosis, and hypercalcemia.
CALCAA gene on chromosome 11p15.2 that encodes peptide hormones calcitonin, calcitonin gene-related peptide and katacalcin, by tissue-specific alternative RNA splicing of gene transcripts and cleavage of inactive precursor peptides. Calcitonin regulates calcium and phosphorus metabolism; calcitonin gene-related peptide is a vasodilator; katacalcin is a calcium-lowering peptide.
calcitoninThyrocalcitonin Physiology A 32 residue polypeptide–plasma levels 100 pg/mL hormone produced by the parafollicular or 'C'–ultimobranchial cells of the thyroid; calcitonin is rapidly secreted in response to ↑ plasma Ca2+, pentagastrin, glucagon, β-adrenergics, and alcohol; it is produced by several neoplasms, especially, medullary CA of thyroid–MCT, which may also be associated with other endocrine tumors ↑ in MCT, small cell of the lung, breast CA. See C cells.
calcitoninSalcatonin or calcitonin (salmon), a hormone secreted by the THYROID gland, independently of the thyroid hormones, and concerned with the control of calcium levels in the blood. It acts on bone to interfere with the release of calcium. It is less important in calcium balance than the parathyroid glands. Used as a drug under the brand name Miacalcic.
calcitonina polypeptide hormone secreted by both the THYROID and PARATHYROID glands that lowers the calcium content of the blood.
calcitonin; thyrocalcitonin hormone (secreted by parafollicular cells of thyroid) reducing plasma calcium (by increasing urinary calcium excretion and reducing osteoclastic bone resorption); used to treat Paget's disease
drug class: synthetic polypeptide calcitonins;
action: inhibits bone resorption, reduces osteoclast function, reduces serum calcium levels in hypercalcemia;
uses: Paget's disease, postmenopausal osteoporosis, hypercalcemia.